CH500944A - Alpha-%aminoalkoxyphenyl-alpha-nitrostilbenes anti - Google Patents

Alpha-%aminoalkoxyphenyl-alpha-nitrostilbenes anti

Info

Publication number
CH500944A
CH500944A CH39168A CH3916865A CH500944A CH 500944 A CH500944 A CH 500944A CH 39168 A CH39168 A CH 39168A CH 3916865 A CH3916865 A CH 3916865A CH 500944 A CH500944 A CH 500944A
Authority
CH
Switzerland
Prior art keywords
alpha
radical
formula
nitro
methoxy
Prior art date
Application number
CH39168A
Other languages
French (fr)
Inventor
Albert De Wald Horace
Original Assignee
Parke Davis & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Parke Davis & Co filed Critical Parke Davis & Co
Priority to CH39168A priority Critical patent/CH500944A/en
Publication of CH500944A publication Critical patent/CH500944A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/205Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic parts with unsaturation outside the rings
    • C07C39/21Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic parts with unsaturation outside the rings with at least one hydroxy group on a non-condensed ring
    • C07C39/215Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic parts with unsaturation outside the rings with at least one hydroxy group on a non-condensed ring containing, e.g. diethylstilbestrol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/46Friedel-Crafts reactions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

(A) alpha-(Aminoalkoxyphenyl)-alpha'-nitrostilbenes of formula: (I) A = ethylene or propylene; R1 and R2 singly = alkyl; or R1 and R2 together = oxydiethylene or alkylene (C4-C8) of which 4 or 5 C atoms form a ring with the N-atom; R3 and R4 = H, halogen, alkyl, alkoxy, CF3. (B) Acid addn. salts of (I). (C) Quaternary ammonium salts of (I). Anti-oestrogenic and hypocholesterolaemic agents for oral or parenteral admin. Prefd. anti-oestrogen is alpha-(p-(2-pyrrolidinoethoxy)-phenyl)-alpha'-nitro-4-methoxy stilbene, prefd. hypocholesterolaemic is alpha-p-(2-diethylaminoethoxy)-phenyl)-alpha'-nitro-4-methoxy-sti- lbene.

Description

  

  
 



  Procédé de préparation de nouveaux composés organiques nitrés
 La présente invention a pour objet un procédé de préparation de nouveaux   a-(aminoalcoxyphényl)-a'-nitro-    stilbènes.



   Sous forme de base libre, ces composés sont représentés par la formule suivante:
EMI1.1     
 dans laquelle A représente un radical éthylène ou propylène; R, et Ra représentent chacun un radical alcoyle inférieur, ou R1 et   R2    sont réunis et représentent ensemble un radical oxydiéthylène, ou un radical alcoylène de 4 à 8 atomes de carbone, dont 4 ou 5 forment un cycle avec l'atome d'azote auquel ils sont fixés; et   Rss    et   Rl    représentent chacun de l'hydrogène, un halogène, un radical alcoyle inférieur, alcoxy inférieur, ou trifluorométhyle. Lorsque R1 et R2 sont réunis et représentent un radical oxydiéthylène, le groupe   - NR1R2    représente le radical morpholino.

  Lorsque   R3    et   R.    sont réunis et représentent un radical alcoylène, le groupe   - NR1R2    représente un radical pyrrolidino, alcoyl-inférieur pyrrolidino, pipéridino ou alcoyl-inférieur pipéridino. Dans les composés de formule ci-dessus, les groupes alcoyles inférieurs préférés sont les groupes méthyle et éthyle; les groupes alcoxy inférieur préférés sont les groupes méthoxy et éthoxy; l'halogène préféré est le chlore: et le groupe A est de préférence le groupe éthylène.



   Le procédé selon l'invention est caractérisé en ce qu'on prépare les composés de formule ci-dessus en faisant réagir un triarylnitroéthylène de formule:
EMI1.2     
  avec une amine de formule:    Hal-A-NR1R2    dans lesquelles formules M est un cation formeur de sel, de préférence un métal alcalin, et Hal est un halogène et les autres symboles ont la même signification que précédemment. On peut ajouter le triarylnitroéthylène de formule ci-dessus au mélange réactionnel comme tel ou on peut le former   in situ   par réaction du phénol correspondant avec une base forte telle que   l'hydrure    de sodium, le méthylate de sodium ou l'hydroxyde de potassium. Les matières de départ peuvent être prises en quantités équivalentes, mais on utilise de préférence un excès modéré de l'amine.

  Comme solvants appropriés pour cette réaction, on peut citer les hydrocarbures aromatiques (par exemple benzène, toluène et xylène), les alcanols inférieurs et le diméthylformamide. En général, on effectue la réaction à un température de   0    à 2000 C ou à la température de reflux du solvant, pendant 30 mn à 24 h, les durées de réaction les plus courtes correspondant aux températures les plus hautes. On peut isoler le produit sous fonne de base libre ou sous forme de sel d'addition d'acide ou de sel d'ammonium quaternaire par ajustage du pH ou par formation d'un sel.



   On peut obtenir les triarylnitroéthylène de départ en faisant réagir une benzophénone de formule:
EMI2.1     
 avec une amine primaire, telle que l'aniline, et en faisant réagir le produit de condensation ainsi formé avec un arylnitrométhane de formule:
EMI2.2     

 On peut également obtenir les matières de départ par d'autres méthodes décrites à titre d'illustration de méthodes avantageuses.



   Les bases libres obtenues par le procédé selon   l'in-    vention forment des sels d'addition d'acide avec divers acides minéraux et organiques. Ainsi, les acides chlorhydrique, bromhydrique, iodhydrique, sulfurique, acétique, benzoïque, citrique,   maléique,    malique, gluconique, ascorbique et   pamoïque    forment des sels d'addition d'acide pharmaceutiquement acceptables. Ces sels d'addition d'acide peuvent être formés par réaction de la base libre avec l'acide choisi, par double décomposition, par échange d'ions ou par un autre moyen de fonnation d'un sel. Les bases libres peuvent également former des sels d'ammonium quaternaire.

  Ainsi, l'iodure de méthyle, le chlorure d'éthyle, le bromure d'éthyle, l'iodure d'éthyle, le chlorure de benzyle et le p-toluène-sulfonate de méthyle forment des sels d'ammonium quaternaire pharmaceutiquement acceptables. Les bases libres et les sels sont généralement équivalents en ce qui concerne les buts de l'invention, sauf que   l'un    ou l'autre peut être préféré en raison de ses propriétés de solubilité particulières. Les bases libres et les sels peuvent tous deux exister comme isomères cis-trans.



   Les composés préparés par le procédé selon l'invention sont des agents pharmacologiques utiles et possèdent en particulier une activité anti-oestrogène, hypocholestérémiante et antifécondité. Pour mesurer l'effet antioestrogène, on administre le composé essayé et un oestrogène classique tel, que l'oestradiol à des animaux ovariectomisés et à la fin de la période d'essais, on compare le poids utérin avec le poids utérin d'animaux ovariectomisés recevant un oestrogène classique sans anti-oestrogène. Dans cette épreuve, une forte activité anti-oestrogène se traduit par un bas poids utérin.

  Comme agents hypocholestérémiants, ils provoquent une diminution du taux du cholestérol sanguin.   L'oc'-    [p - (2 - pyrrolidino   éthoxy)-phényl]-a'-nitro-4-méthoxy-stilbène    est un composé anti-oestrogène et antifécondité préféré, alors que   l'a'-    [p - (2 - diéthylamino - éthoxy) - phényl] -   a'-nitro-4-mé-    thoxy-stilbène est un hypocholestérémiant préféré. Ces nouveaux composés sont actifs par voie orale mais peuvent également être administrés par voie parentérale.



   Exemple
 Sous agitation, on ajoute peu à peu 1,0 g d'une dispersion d'hydrure de sodium à   500/0    dans de l'huile minérale à une solution de 7 g   d'a'-(p-hydroxy-phényl)-      (X.'-nitro-4-méthoxy-stilbène    dans 75ml de diméthylformamide. Après   10 mon,    on ajoute une solution de   N-(o-    chloro-éthyl)-pyrrolidine (préparée par basification de 10g de chlorhydrate) dans   200ml    d'éther. On chauffe lentement le mélange à 900 C et on le maintient à 900 C pendant 2 h, en l'agitant continuellement.

  Ensuite, on le refroidit, on le dilue avec 300 ml de benzène, on le lave à l'eau, avec une solution d'hydroxyde de sodium diluée et avec une solution de chlorure de sodium, on le sèche et on l'évapore, obtenant ainsi comme résidu de   l'a'- [p-    (2-pyrrolidino-éthoxy)-phényl]   - a'- nitro -4- méthoxy    - stil   bène;    p. f.   118-1200 C    après cristallisation dans du méthanol. On obtient le monocitrate en faisant réagir 4,4 g de la base libre avec 2 g d'acide citrique dans 50 ml de   méthyléthylcétone;    p. f. 850 C.



   On peut obtenir la matière de départ comme suit: on chauffe un mélange de 22 g de 4-hydroxy-4'-méthoxybenzophénone, de 19 g d'aniline et de 0,5 g de chlorhydrate d'aniline sous azote, dans un bain d'huile à 1800 C pendant 1 h. On laisse refroidir le mélange et on le cristallise dans de l'éthanol à 95   O/o,    obtenant ainsi le produit de condensation purifié de la 4-hydroxy-4'-méthoxybenzophénone et de l'aniline; p. f. 1100 C. On laisse reposer une solution de 14 g de ce produit de condensation et de 7 g de phénylnitrométhane dans 20 ml d'acide acétique et 10   ml    d'anhydride acétique à la température ordinaire pendant 18 h, puis on le coule dans de   l'veau    et on l'extrait au chloroforme. 

  On lave la solution   chloro-    formique à l'eau, on la   sèche et    on l'évapore sous pres  sion réduite, ce qui laisse comme résidu l'a-(p-hydroxy   phényl)- '-nitro-4-méthoxy-stilbène.   



   On peut également obtenir cette matière de départ comme suit. On prépare de   l' '-nitro-4-benzyloxy-stil-    bène en ajoutant peu à peu 21 g de phénylnitrométhane dans 25   ml    d'acide acétique à 39 g du produit de condensation du p-benzyloxy-benzaldéhyde avec la butylamine, dissous dans 25   ml    d'acétique. On ajoute peu à peu une solution de 33 g   d'a'- nitro -4-      benzyloxy - stilbène    dans   100 mi    d'éther, sous agitation, à un mélange   réactionnei    refroidi, préparé à partir de 19 g de p-bromo-anisole et de 2,5 g de magnésium dans 150   ml    d'éther. On chauffe le mélange à reflux pendant 15 mn, puis on le refroidit à   -200C    et on lui ajoute goutte à goutte 16g de brome.



   On supprime la réfrigération externe et, après 30 mn, on recueille le   1 -(p-méthoxy-phényl)- 1 -(p-benzyloxy-phé-    nyl)-2-bromo-2-nitro-2-phényl-éthane qui s'est formé et on le lave avec une petite quantité d'éther. On chauffe ce produit à reflux pendant 1 h dans 250   ml    de méthanol contenant 25g de méthylate de sodium et obtient de   I'  - (p - benzyloxy -    phényl) -   a'-      nitro-4-méthoxy-stilbène;    p. f.   1250 C    après cristallisation dans de l'acide acétique.

 

  On chauffe 10g de ce composé à reflux pendant   lh    avec   75ml    d'acide acétique et   75 mol    d'acide chlorhydrique concentré. On concentre le mélange par distillation sous vide jusqu'à un faible volume, on le dilue avec de l'eau et on l'extrait au chloroforme. On sèche la solution chloroformique et on l'évapore, ce qui laisse comme résidu de   l'a - (p - hydroxy -    phényl) -   a.'-    nitro - 4 - méthoxystilbène. 



  
 



  Process for the preparation of new organic nitro compounds
 The present invention relates to a process for the preparation of novel α- (aminoalkoxyphenyl) -a'-nitro-stilbènes.



   In the free base form, these compounds are represented by the following formula:
EMI1.1
 in which A represents an ethylene or propylene radical; R, and Ra each represent a lower alkyl radical, or R1 and R2 are united and together represent an oxidiethylene radical, or an alkylene radical of 4 to 8 carbon atoms, 4 or 5 of which form a ring with the nitrogen atom to which they are attached; and Rss and Rl each represent hydrogen, halogen, lower alkyl, lower alkoxy, or trifluoromethyl. When R1 and R2 are combined and represent an oxidiethylene radical, the group - NR1R2 represents the morpholino radical.

  When R3 and R. are combined and represent an alkylene radical, the group - NR1R2 represents a pyrrolidino, lower alkyl pyrrolidino, piperidino or lower alkyl piperidino radical. In the compounds of the above formula, the preferred lower alkyl groups are methyl and ethyl groups; preferred lower alkoxy groups are methoxy and ethoxy groups; the preferred halogen is chlorine: and the group A is preferably the ethylene group.



   The method according to the invention is characterized in that the compounds of formula above are prepared by reacting a triarylnitroethylene of formula:
EMI1.2
  with an amine of the formula: Hal-A-NR1R2 in which formulas M is a salt-forming cation, preferably an alkali metal, and Hal is a halogen and the other symbols have the same meaning as above. The triarylnitroethylene of the above formula can be added to the reaction mixture as such or it can be formed in situ by reacting the corresponding phenol with a strong base such as sodium hydride, sodium methoxide or potassium hydroxide. The starting materials can be taken in equivalent amounts, but preferably a moderate excess of the amine is used.

  Suitable solvents for this reaction are aromatic hydrocarbons (for example benzene, toluene and xylene), lower alkanols and dimethylformamide. In general, the reaction is carried out at a temperature of 0 to 2000 ° C. or at the reflux temperature of the solvent, for 30 minutes to 24 hours, the shorter reaction times corresponding to the highest temperatures. The product can be isolated as the free base or as an acid addition salt or quaternary ammonium salt by adjusting the pH or by forming a salt.



   The starting triarylnitroethylene can be obtained by reacting a benzophenone of formula:
EMI2.1
 with a primary amine, such as aniline, and by reacting the condensation product thus formed with an arylnitromethane of formula:
EMI2.2

 The starting materials can also be obtained by other methods described by way of illustration of advantageous methods.



   The free bases obtained by the process according to the invention form acid addition salts with various inorganic and organic acids. Thus, hydrochloric, hydrobromic, hydriodic, sulfuric, acetic, benzoic, citric, maleic, malic, gluconic, ascorbic and pamoic acids form pharmaceutically acceptable acid addition salts. These acid addition salts can be formed by reaction of the free base with the selected acid, by double decomposition, by ion exchange or by other means of forming a salt. The free bases can also form quaternary ammonium salts.

  Thus, methyl iodide, ethyl chloride, ethyl bromide, ethyl iodide, benzyl chloride and methyl p-toluenesulphonate form pharmaceutically acceptable quaternary ammonium salts. The free bases and the salts are generally equivalent for the purposes of the invention, except that one or the other may be preferred due to its particular solubility properties. Both free bases and salts can exist as cis-trans isomers.



   The compounds prepared by the process according to the invention are useful pharmacological agents and in particular possess antiestrogenic, hypocholesteremic and anti-fertility activity. To measure the antiestrogenic effect, the test compound and a conventional estrogen such as estradiol are administered to ovariectomized animals and at the end of the test period, the uterine weight is compared with the uterine weight of ovariectomized animals. receiving conventional estrogen without anti-estrogen. In this test, strong antiestrogenic activity results in low uterine weight.

  As cholesterol-lowering agents, they cause a decrease in blood cholesterol levels. Oc'- [p - (2 - pyrrolidino ethoxy) -phenyl] -a'-nitro-4-methoxy-stilbene is a preferred anti-estrogen and antifertility compound, while a'- [p - (2 - diethylamino - ethoxy) - phenyl] - a'-nitro-4-methoxy-stilbene is a preferred hypocholesteremic agent. These new compounds are active orally but can also be administered parenterally.



   Example
 With stirring, 1.0 g of a dispersion of 500/0 sodium hydride in mineral oil is gradually added to a solution of 7 g of a '- (p-hydroxy-phenyl) - (X .'-nitro-4-methoxy-stilbene in 75ml of dimethylformamide. After 10 ml, a solution of N- (o-chloro-ethyl) -pyrrolidine (prepared by basification of 10g of hydrochloride) in 200ml of hydrochloride is added. Ether The mixture is slowly heated to 900 ° C. and maintained at 900 ° C. for 2 h, with continuous stirring.

  Then it is cooled, diluted with 300 ml of benzene, washed with water, with dilute sodium hydroxide solution and with sodium chloride solution, dried and evaporated, thus obtaining as a residue a'- [p- (2-pyrrolidino-ethoxy) -phenyl] - a'- nitro -4-methoxy-stilbene; p. f. 118-1200 C after crystallization from methanol. The monocitrate is obtained by reacting 4.4 g of the free base with 2 g of citric acid in 50 ml of methyl ethyl ketone; p. f. 850 C.



   The starting material can be obtained as follows: a mixture of 22 g of 4-hydroxy-4'-methoxybenzophenone, 19 g of aniline and 0.5 g of aniline hydrochloride is heated under nitrogen in a bath. of oil at 1800 C for 1 h. The mixture is allowed to cool and crystallized from 95 O / o ethanol, thereby obtaining the purified condensation product of 4-hydroxy-4'-methoxybenzophenone and aniline; p. f. 1100 C. A solution of 14 g of this condensation product and 7 g of phenylnitromethane in 20 ml of acetic acid and 10 ml of acetic anhydride is allowed to stand at room temperature for 18 h, then it is poured into water. veal and extracted with chloroform.

  The chloroform solution is washed with water, dried and evaporated under reduced pressure, leaving a- (p-hydroxy phenyl) - '-nitro-4-methoxy-stilbene as residue. .



   This starting material can also be obtained as follows. '-Nitro-4-benzyloxy-stilbene is prepared by gradually adding 21 g of phenylnitromethane in 25 ml of acetic acid to 39 g of the condensation product of p-benzyloxy-benzaldehyde with butylamine, dissolved. in 25 ml of acetic. A solution of 33 g of a'-nitro -4-benzyloxy - stilbene in 100 ml of ether is gradually added, with stirring, to a cooled reaction mixture, prepared from 19 g of p-bromo-anisole. and 2.5 g of magnesium in 150 ml of ether. The mixture is heated at reflux for 15 min, then cooled to -200C and 16g of bromine is added dropwise thereto.



   External refrigeration is removed and, after 30 minutes, the 1 - (p-methoxy-phenyl) - 1 - (p-benzyloxy-phenyl) -2-bromo-2-nitro-2-phenyl-ethane is collected which formed and washed with a small amount of ether. This product is refluxed for 1 h in 250 ml of methanol containing 25 g of sodium methoxide and I '- (p - benzyloxy - phenyl) - a' - nitro-4-methoxy-stilbene is obtained; p. f. 1250 C after crystallization from acetic acid.

 

  10 g of this compound are heated at reflux for 1 h with 75 ml of acetic acid and 75 mol of concentrated hydrochloric acid. The mixture is concentrated by vacuum distillation to a small volume, diluted with water and extracted with chloroform. The chloroform solution was dried and evaporated, leaving a - (p - hydroxy - phenyl) - a .'-nitro - 4 - methoxystilbene residue.

 

Claims (1)

REVENDICATION CLAIM Procédé de préparation des composés de formule: EMI3.1 dans laquelle A représente un radical éthylène ou pro pylène; Ri et RW représentent chacun un radical alcoyle inférieur, ou Rl et R. sont réunis et représentent ensemble: a) un radical oxydiéthylène, b) un radical alcoylène de 4 à 8 atomes de carbone, dont 4 ou 5 forment un cycle avec l'atome d'azote; Process for preparing the compounds of formula: EMI3.1 in which A represents an ethylene or propylene radical; Ri and RW each represent a lower alkyl radical, or Rl and R. are united and together represent: a) an oxydiethylene radical, b) an alkylene radical of 4 to 8 carbon atoms, 4 or 5 of which form a ring with the nitrogen atom; et R3 et RA représentent chacun de l'hydrogène, un halogène, un radical alcoyle inférieur, alcoxy inférieur, ou trifluorométhyle, caractérisé en ce que l'on fait réagir un composé de formule: EMI3.2 dans laquelle M représente un cation formeur de sel et Hal représente un halogène, avec une amine de formule: Hal - A - NRtR2 SOUS-REVENDICATIONS 1. Procédé selon la revendication, caractérisé en ce que M représente un métal alcalin. and R3 and RA each represent hydrogen, a halogen, a lower alkyl, lower alkoxy or trifluoromethyl radical, characterized in that a compound of formula is reacted: EMI3.2 in which M represents a salt-forming cation and Hal represents a halogen, with an amine of the formula: Hal - A - NRtR2 SUB-CLAIMS 1. Method according to claim, characterized in that M represents an alkali metal. 2. Procédé selon la revendication, caractérisé en ce que A représente le radical éthylène, R1 et R2 sont réunis et représentent ensemble le radical pyrrolidino, RS représente le radical 4-méthoxy et R4 représente de l'hydrogène. 2. Method according to claim, characterized in that A represents the ethylene radical, R1 and R2 are combined and together represent the pyrrolidino radical, RS represents the 4-methoxy radical and R4 represents hydrogen. 3. Procédé selon la revendication ou l'une des sousrevendications précédentes, caractérisé en ce que l'on transforme le produit obtenu en un sel. 3. Method according to claim or one of the preceding subclaims, characterized in that the product obtained is converted into a salt.
CH39168A 1965-12-21 1965-12-21 Alpha-%aminoalkoxyphenyl-alpha-nitrostilbenes anti CH500944A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CH39168A CH500944A (en) 1965-12-21 1965-12-21 Alpha-%aminoalkoxyphenyl-alpha-nitrostilbenes anti

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH1762565A CH479539A (en) 1965-12-21 1965-12-21 Process for the preparation of a- (aminoalkoxyphenyl) -a'nitrostilbenes
CH39168A CH500944A (en) 1965-12-21 1965-12-21 Alpha-%aminoalkoxyphenyl-alpha-nitrostilbenes anti

Publications (1)

Publication Number Publication Date
CH500944A true CH500944A (en) 1970-12-31

Family

ID=4426816

Family Applications (5)

Application Number Title Priority Date Filing Date
CH1762565A CH479539A (en) 1965-12-21 1965-12-21 Process for the preparation of a- (aminoalkoxyphenyl) -a'nitrostilbenes
CH39268A CH500945A (en) 1965-12-21 1965-12-21 Alpha-%aminoalkoxyphenyl-alpha-nitrostilbenes anti
CH39068A CH500943A (en) 1965-12-21 1965-12-21 Alpha-%aminoalkoxyphenyl-alpha-nitrostilbenes anti
CH39168A CH500944A (en) 1965-12-21 1965-12-21 Alpha-%aminoalkoxyphenyl-alpha-nitrostilbenes anti
CH38968A CH500942A (en) 1965-12-21 1965-12-21 Alpha-%aminoalkoxyphenyl-alpha-nitrostilbenes anti

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CH1762565A CH479539A (en) 1965-12-21 1965-12-21 Process for the preparation of a- (aminoalkoxyphenyl) -a'nitrostilbenes
CH39268A CH500945A (en) 1965-12-21 1965-12-21 Alpha-%aminoalkoxyphenyl-alpha-nitrostilbenes anti
CH39068A CH500943A (en) 1965-12-21 1965-12-21 Alpha-%aminoalkoxyphenyl-alpha-nitrostilbenes anti

Family Applications After (1)

Application Number Title Priority Date Filing Date
CH38968A CH500942A (en) 1965-12-21 1965-12-21 Alpha-%aminoalkoxyphenyl-alpha-nitrostilbenes anti

Country Status (1)

Country Link
CH (5) CH479539A (en)

Also Published As

Publication number Publication date
CH500943A (en) 1970-12-31
CH479539A (en) 1969-10-15
CH500942A (en) 1970-12-31
CH500945A (en) 1970-12-31

Similar Documents

Publication Publication Date Title
FR2472564A1 (en) 1-Aryl-4-aryl:sulphonyl-3-amino-propoxy-1H-pyrazole derivs. - hypolipaemics and hypocholesterolaemics of low toxicity and non-ulcerogenic
EP0025727B1 (en) Indole derivatives, process for their preparation and medicaments containing them
EP0110755B1 (en) Piperidine dione derivatives with a myocardium protecting and antiarrhytmic activity, process for their preparation and medicines containing them
CH407088A (en) Process for the preparation of 4-halo-3-sulfamoyl-benzoic acid derivatives
EP0122827A1 (en) 1-(2-Ethoxycarbonyl-4-phenylalkylamido)-3-amino-2-propanols, their preparations and their medicinal uses
EP0327455A1 (en) Alkyl or benzyl ethers of phenol, processes for their preparation and their therapeutical use
FR2487827A1 (en) NOVEL DERIVATIVES OF PHENETYLAMINE AND PROCESS FOR THEIR PRODUCTION
CH500944A (en) Alpha-%aminoalkoxyphenyl-alpha-nitrostilbenes anti
EP0074873A1 (en) Derivatives of 3-phenoxy-3-propanol, their preparation and their therapeutic use
FR2528422A1 (en) NOVEL 1,2,3,4-TETRAHYDRONAPHTALENE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THESE DERIVATIVES
EP0005654B1 (en) Process for the isomerization of 3-vinyl-piperidine derivatives
EP0002401B1 (en) Derivatives of naphthalene, process for their preparation and their therapeutic application
CH380134A (en) Process for the preparation of novel phenothiazine derivatives
CH407087A (en) Process for the preparation of new derivatives of diphenylacetamide
EP0082058A1 (en) Ethers of oximes of 1-pyridyl-3-pentanone, process for their preparation and their use as a drug
FR2602228A1 (en) New phenoxyisobutyric acids, their derivatives and processes for producing them
CH623818A5 (en) Process for producing derivatives of thiochroman
FR2508445A1 (en) NOVEL BENZOYL-PHENYL-PIPERIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND THEIR USE, IN PARTICULAR THERAPEUTICS
EP0082059A1 (en) Alpha-Beta-unsaturated oxime ethers, process for their preparation and their use as medicines
CH420107A (en) Process for the preparation of new substituted aralkylaminoalkylcyclohexane derivatives
CH641764A5 (en) IMIDOESTER SALTS AND PROCESS FOR THE SYNTHESIS OF 2-NAPHTHALENE-ETHANIMIDAMIDE N, NON-DISUBSTITUTED FROM SAID SALTS.
CH396007A (en) Manufacturing process for new piperazine derivatives
CH395126A (en) Process for preparing quaternary ammonium compounds
BE722813A (en)
CH376491A (en) Process for the preparation of substituted triphenylethylenes

Legal Events

Date Code Title Description
PL Patent ceased